Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics Inc.

In a report released today, Sadia Rahman from Wells Fargo maintained a Buy rating on Dianthus Therapeutics, with a price target of $135.00. In addi...

Dianthus Therapeutics (DNTH) Receives a Buy from Wells Fargo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dianthus Therapeutics (DNTH), Equillium (EQ) and Kod...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNTH	$88.37	+2.52%	503.00K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNTH	$88.37	+2.5%	503.00K
3
4
5
6

DNTH

DNTH

Latest News for DNTH

Get Dianthus Therapeutics Inc. Data in Excel

Get Dianthus Therapeutics Inc. Data in Excel